148 related articles for article (PubMed ID: 30723672)
1. Perampanel in lissencephaly-associated epilepsy.
Ikemoto S; Hamano SI; Hirata Y; Matsuura R; Koichihara R
Epilepsy Behav Case Rep; 2019; 11():67-69. PubMed ID: 30723672
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of perampanel for controlling seizures and improving neurological dysfunction in a patient with dentatorubral-pallidoluysian atrophy (DRPLA).
Shiraishi H; Egawa K; Ito T; Kawano O; Asahina N; Kohsaka S
Epilepsy Behav Case Rep; 2017; 8():44-46. PubMed ID: 28856097
[TBL] [Abstract][Full Text] [Related]
3. Perampanel as monotherapy and adjunctive therapy for focal onset seizures, focal to bilateral tonic-clonic seizures and as adjunctive therapy of generalized onset tonic-clonic seizures.
Tyrlikova I; Brazdil M; Rektor I; Tyrlik M
Expert Rev Neurother; 2019 Jan; 19(1):5-16. PubMed ID: 30560703
[No Abstract] [Full Text] [Related]
4. Perampanel in routine clinical use in idiopathic generalized epilepsy: The 12-month GENERAL study.
Villanueva V; Montoya J; Castillo A; Mauri-Llerda JÁ; Giner P; López-González FJ; Piera A; Villanueva-Hernández P; Bertol V; Garcia-Escrivá A; Garcia-Peñas JJ; Garamendi I; Esteve-Belloch P; Baiges-Octavio JJ; Miró J; Falip M; Garcés M; Gómez A; Gil-López FJ; Carreño M; Rodriguez-Uranga JJ; Campos D; Bonet M; Querol R; Molins A; Tortosa D; Salas-Puig J
Epilepsia; 2018 Sep; 59(9):1740-1752. PubMed ID: 30062784
[TBL] [Abstract][Full Text] [Related]
5. Perampanel: Does it have broad-spectrum potential?
Potschka H; Trinka E
Epilepsia; 2019 Mar; 60 Suppl 1():22-36. PubMed ID: 29953584
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of perampanel as monotherapy for focal seizures: Experience from open-label extension studies.
Kwan P; Mintzer S; Laurenza A; Patten A; Cartwright K
Epilepsy Behav Case Rep; 2018; 9():1-5. PubMed ID: 29707476
[TBL] [Abstract][Full Text] [Related]
7. Perampanel as adjunctive therapy in highly refractory epilepsies: Real-world data from an Italian tertiary care epilepsy centre.
Morano A; Fattouch J; Albini M; Casciato S; Fanella M; Basili LM; Viganò A; Manfredi M; Giallonardo AT; Di Bonaventura C
J Neurol Sci; 2018 Jul; 390():67-74. PubMed ID: 29801910
[TBL] [Abstract][Full Text] [Related]
8. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of perampanel for partial-onset and primary generalized tonic-clonic seizures.
Besag FM; Patsalos PN
Neuropsychiatr Dis Treat; 2016; 12():1215-20. PubMed ID: 27274257
[TBL] [Abstract][Full Text] [Related]
10. AMPA receptors and perampanel behind selected epilepsies: current evidence and future perspectives.
Di Bonaventura C; Labate A; Maschio M; Meletti S; Russo E
Expert Opin Pharmacother; 2017 Nov; 18(16):1751-1764. PubMed ID: 29023170
[TBL] [Abstract][Full Text] [Related]
11. Perampanel: A Review in Drug-Resistant Epilepsy.
Frampton JE
Drugs; 2015 Sep; 75(14):1657-68. PubMed ID: 26370209
[TBL] [Abstract][Full Text] [Related]
12. Perampanel for the treatment of primary generalized tonic-clonic seizures in idiopathic generalized epilepsy.
Rohracher A; Brigo F; Höfler J; Kalss G; Neuray C; Dobesberger J; Kuchukhidze G; Leitinger M; Trinka E
Expert Opin Pharmacother; 2016 Jul; 17(10):1403-11. PubMed ID: 27267634
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of perampanel in pediatric patients with Dravet syndrome.
Yoshitomi S; Takahashi Y; Yamaguchi T; Imai K; Ishii A; Hirose S; Inoue Y
Epilepsy Res; 2019 Aug; 154():34-38. PubMed ID: 31035242
[TBL] [Abstract][Full Text] [Related]
14. The AMPA receptor antagonist perampanel is a new hope in the treatment for epilepsy.
El Desoky ES
Fundam Clin Pharmacol; 2014 Oct; 28(5):473-80. PubMed ID: 24750493
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study.
Singh K; Shah YD; Luciano D; Friedman D; Devinsky O; Kothare SV
Epilepsy Behav; 2016 Aug; 61():41-45. PubMed ID: 27300147
[TBL] [Abstract][Full Text] [Related]
16. Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy.
Ishikawa N; Tateishi Y; Tani H; Kobayashi Y; Kobayashi M
Epilepsy Behav; 2019 May; 94():82-86. PubMed ID: 30897534
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of perampanel in a patient with epilepsia partialis continua.
Argente-Escrig H; Gómez-Ibáñez A; Villanueva V
Epilepsy Behav Case Rep; 2017; 8():105-107. PubMed ID: 29062692
[TBL] [Abstract][Full Text] [Related]
18. Retrospective study of perampanel efficacy and tolerability in myoclonic seizures.
Gil-López FJ; Montoya J; Falip M; Aparicio J; López-González FJ; Toledano R; Gil-Nagel A; Molins A; García I; Serrano P; Domenech G; Torres F; Donaire A; Carreño M
Acta Neurol Scand; 2018 Aug; 138(2):122-129. PubMed ID: 29573400
[TBL] [Abstract][Full Text] [Related]
19. Electroclinical features of epilepsy in patients with juvenile type dentatorubral-pallidoluysian atrophy.
Egawa K; Takahashi Y; Kubota Y; Kubota H; Inoue Y; Fujiwara T; Onodera O
Epilepsia; 2008 Dec; 49(12):2041-9. PubMed ID: 18616556
[TBL] [Abstract][Full Text] [Related]
20. Perampanel, an antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent models.
Zwart R; Sher E; Ping X; Jin X; Sims JR; Chappell AS; Gleason SD; Hahn PJ; Gardinier K; Gernert DL; Hobbs J; Smith JL; Valli SN; Witkin JM
J Pharmacol Exp Ther; 2014 Oct; 351(1):124-33. PubMed ID: 25027316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
